On April 26, 2021 Applied Cells, a commercial provider of cell preparation and isolation solutions for tumor biology research, reported that it will further its research collaboration on rare cell isolation of breast cancer disseminated tumor cells in bone marrow with the Perelman School of Medicine at the University of Pennsylvania (Penn)(Press release, Applied Cells, APR 26, 2021, View Source;utm_medium=rss&utm_campaign=applied-cells-inc-enters-collaborative-research-agreement-for-the-development-of-rare-cell-isolation-in-minimum-residual-disease [SID1234584031]). Applied Cells MARS technologies will be used in a multi-center trial as part of the 2-PREVENT (Secondary PREvention through SurVEillance and iNTervention) Translational Center of Excellence to evaluate their potential role in the detection of breast cancer minimum residual disease.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Penn’s 2-PREVENT program focuses on the collaboration of clinical and basic science researchers with the goal of improving the surveillance, prevention, and treatment of recurrent breast cancer. Applied Cells MARS technologies will be evaluated in clinical trials to determine whether they will successfully pre-enrich extremely low frequency cancer cells in bone marrow samples that might result in high recovery. Applied Cells MARS workflow reduces human factors and ensures standardized operation, which are required for the trial.
"I am glad our MARS technologies will have the opportunity to be tested for ability to provide simplicity and desired performance," said Dr. Yuchen Zhou, CEO of Applied Cells. "We are very excited to further our collaboration with Penn Medicine to utilize MARS to investigate whether this technology can advance the detection of rare cancer cells in a multi-center breast cancer trial."
"If successful, it will allow us to refine and extend our efforts to detect ultra-rare disseminated tumor cells in breast cancer patients with early stage disease," said Dr. Lewis Chodosh, Chairman of the Department of Cancer Biology in the Perelman School of Medicine at the University of Pennsylvania. "We believe this approach has the potential to markedly improve the sensitivity with which this critical reservoir of cancer cells can be detected and characterized in patients – which will need to be confirmed in clinical trials.